|
Carrillo-Aleman L, Marin F, Rivera-Caravaca JM, Vicente-Ibarra N, Candela-Sanchez E, Esteve-Pastor MA, Lozano T, Sandin-Rollan M, Pernias-Escrig V, Macias M, Quintana-Giner M, Veliz A, Orenes-Pinero E, Martinez-Martinez JG, Ruiz-Nodar JM. Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. Clin Drug Investig. 2019 Mar;39(3):275-283. doi: 10.1007/s40261-018-0736-z. PubMed PMID: 30623372.
AÑO: 2019; IF: 2.267
|
30623372
|
Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019. PubMed PMID: 31169831; PubMed Central PMCID: PMC6482585.
AÑO: 2019; IF: 2.295
|
|
Ferreiro J.L., Vivas D., De La Hera J.M., Marcano A.L., Lugo L.M., Gómez-Polo J.C., Silva I., Tello-Montoliu A., Marín F., Roldán I. High and low on-treatment platelet reactivity to P2Y <inf>12</inf> inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research. March 2019. 175:95-101. 10.1016/j.thromres.2019.01.021
AÑO: 2019; IF: 2.869
|
|
SEC Working Group for the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy; Expert Reviewers for the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy; SEC Guidelines Committee. Comentarios a la guia ESC 2018 sobre el tratamiento de las enfermedades cardiovasculares durante el embarazo. Rev Esp Cardiol (Engl Ed). 2019 Feb;72(2):109-114. doi: 10.1016/j.rec.2018.12.002. No abstract available. English, Spanish. PubMed PMID: 30704722.
AÑO: 2019; IF: 4.642
|
|
Hernandez-Romero D, Sanchez-Quinones J, Vilchez JA, Rivera-Caravaca JM, de la Morena G, Lip GYH, Climent V, Marin F. Galectin-3 and beta-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Sci Rep. 2019 Apr 17;9(1):6235. doi: 10.1038/s41598-019-42727-4. PubMed PMID: 30996283; PubMed Central PMCID: PMC6470309.
AÑO: 2019; IF: 3.998
|